| Dr Robert Ian Noble, MD | |
|
832 S Montana St, Butte, MT 59701-2836 | |
| (406) 723-4004 | |
| Not Available |
| Full Name | Dr Robert Ian Noble |
|---|---|
| Gender | Male |
| Speciality | Ophthalmology |
| Location | 832 S Montana St, Butte, Montana |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1124024351 | NPI | - | NPPES |
| 05560 | Other | MT | BLUE CROSS/BLUE SHIELD |
| 2-9588 | Medicaid | MT | |
| 556 | Other | MT | PIN |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207W00000X | Ophthalmology | 4391 (Montana) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Dr Robert Ian Noble, MD 832 S Montana St, Butte, MT 59701-2836 Ph: (406) 723-4004 | Dr Robert Ian Noble, MD 832 S Montana St, Butte, MT 59701-2836 Ph: (406) 723-4004 |
News Archive
GE Healthcare, a unit of GE, and Intel Corporation (NASDAQ:INTC) announced today that they have expanded their sales and marketing agreement for the Intel Health Guide to include the United Kingdom. GE Healthcare already markets the Intel Health Guide in the United States.
While all Americans will eventually die, CBS's 60 Minutes reports, it may turn some heads to find out how much the government will spend when it happens - in 2008, about $50 billion in the last two months of life. "You might think this would be an obvious thing for Congress and the president to address as they try to reform health care. But what used to be a bipartisan issue has become a politically explosive one - a perfect example of the costs that threaten to bankrupt the country and how hard it's going to be to rein them in."
A trial of an experimental drug to treat advanced liver cancer has helped extend patients lives by as much as three months.
In the first major trial of its kind, Cleveland Clinic researchers used a blinded rechallenge with atorvastatin or placebo to objectively confirm the presence of muscle-related symptoms in patients with a history of intolerance to multiple statins and found that evolocumab (a PCSK9 inhibitor) was a more effective option to lower cholesterol than ezetimibe in these patients.
› Verified 6 days ago
Bartholomew Andrew Martyak, MD Ophthalmology Medicare: Not Enrolled in Medicare Practice Location: 3417 Busch St, Butte, MT 59701 Phone: 406-541-3937 Fax: 406-541-1810 | |
Dr. David G Shapnick, M.D. Ophthalmology Medicare: Not Enrolled in Medicare Practice Location: 401 S Alabama St, Butte, MT 59701 Phone: 406-782-3808 Fax: 406-782-3802 | |
Clay Daniel Holley, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 3417 Busch St, Butte, MT 59701 Phone: 406-494-3145 | |
Dr. Richard T Tschetter, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 832 S Montana St, Butte, MT 59701 Phone: 406-723-4004 Fax: 406-782-4567 |